Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05989711

Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) (IMPACT Trial) — IMPACT  

Non-Alcoholic Steatohepatitis (NASH) Clinical Trial

Official title:
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)

Clinical Trial Summary

Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.

Clinical Trial Description

A Phase 2, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in NASH. ;

Study Design

Related Conditions & MeSH terms

  • Fatty Liver
  • Non-alcoholic Fatty Liver Disease
  • Non-Alcoholic Steatohepatitis (NASH)
Clinical Trial Details
NCT number NCT05989711
Study type Interventional
Source Altimmune, Inc.
Contact Altimmune CTM
Phone 2406541450
Email information@altimmune.com
Status Recruiting
Phase Phase 2
Start date July 27, 2023
Completion date September 30, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04481594 - A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects Phase 1
Recruiting NCT06151964 - A Trial to Learn How Safe AZD9550 is in People With Type 2 Diabetes Who Are Overweight or Obese Phase 1/Phase 2
Completed NCT04019561 - A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH. Phase 2
Completed NCT01694849 - Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) Phase 2
Completed NCT02653300 - A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH) Phase 2
Completed NCT03517540 - Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis Phase 2
Withdrawn NCT05050721 - Natural History of Non Alcoholic Fatty Liver Disease and Predictors of Advanced Fibrosis
Active, not recruiting NCT04682600 - The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF N/A
Enrolling by invitation NCT01950884 - Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Phase 4
Completed NCT04483947 - A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients Phase 1
Completed NCT02927314 - A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease Phase 2
Active, not recruiting NCT02612662 - A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects Phase 1
Recruiting NCT06168383 - To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) . Phase 2
Terminated NCT02605616 - Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD) Phase 2
Completed NCT02158351 - Gut Microbiota and Modulation of Liver Damage in NAFLD
Recruiting NCT03151473 - Longitudinal Observational Study Of Chinese With NAFLD/NASH
Recruiting NCT04820036 - A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG) N/A
Recruiting NCT05553470 - Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant Phase 1
Recruiting NCT04639414 - Combined Active Treatment in Type 2 Diabetes With NASH Phase 4
Withdrawn NCT04607655 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis Phase 1/Phase 2